Law Firms Target Multiple Public Companies

The lawsuit against Smart Digital Group alleges a market manipulation scheme where social media misinformation and impersonators posing as financial professionals were used to inflate the stock price. Insiders also allegedly planned to use offshore accounts to dump shares during this inflation campaign. Following these revelations, the SEC suspended trading of SDM securities, and the stock price plummeted 86.4% on September 26, 2025. Aquestive Therapeutics is under scrutiny after the FDA identified deficiencies in the company's New Drug Application for Anaphylm, a sublingual film for treating severe allergic reactions. The company's announcement on January 9, 2026, which did not specify the nature of the deficiencies, led to a more than 37% drop in its stock price. Hub Group, a major freight transportation provider, announced on February 5, 2026, that it will need to restate its financial statements for the first three quarters of 2025. The company disclosed an error that resulted in the understatement of purchased transportation costs and accounts payable. This news caused Hub Group's stock to fall over 24%. These investor-led lawsuits are a common feature of the U.S. financial markets, though the number of new federal securities class action filings in 2025, at 207, was down 11% from 2024. Despite the decrease in filings, the median settlement value for such cases in 2025 reached a ten-year high of $17.3 million. The legal process for these cases typically involves a court appointing a lead plaintiff to represent the entire class of affected investors. These proceedings can be lengthy, often taking two to three years or more to reach a resolution, which most commonly comes in the form of a settlement. While filings related to SPACs and COVID-19 have declined, cases involving AI and cryptocurrency-related claims saw an increase in 2025. The healthcare and technology sectors combined accounted for 57% of all new securities class action filings during the year.